Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype

Figure 1

Effects of dasatinib on c-Src phosphorylation in MDA-MB-231 cells. Breast cancer cells were treated with indicated concentrations of dasatinib for 24 hours. The expression levels of c-Src, p-Src (Y416) and p-Src (Y527) were measured by the immunocytochemical analysis described in the Materials and Methods. Dasatinib dose-dependently decreased the expression levels of p-Src (Y416 and Y-527) but not that of c-Src.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us